<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="23899">Eicosanoids</z:chebi> (<z:chebi fb="11" ids="26333">prostaglandins</z:chebi> and <z:chebi fb="0" ids="25029">leukotrienes</z:chebi>) may contribute to the clinical manifestations of <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In this cross-sectional study, our purpose was to assess the role of <z:chebi fb="0" ids="15647">leukotriene B4</z:chebi> (<z:chebi fb="0" ids="15647">LTB4</z:chebi>) and <z:chebi fb="0" ids="15551">prostaglandin E2</z:chebi> (<z:chebi fb="0" ids="15551">PGE2</z:chebi>) in the clinical, endoscopic, and histological manifestations of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Using RIA, we measured ex vivo <z:chebi fb="0" ids="15647">LTB4</z:chebi> and <z:chebi fb="0" ids="15551">PGE2</z:chebi> content in esophageal mucosal biopsies from 141 patients with or without <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> who underwent upper endoscopy </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were classified as <z:mpath ids='MPATH_458'>normal</z:mpath> symptomatic controls(n = 70), <z:hpo ids='HP_0100633'>esophagitis</z:hpo> stages 1-4 (n = 60), and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (n = 11), using clinical, endoscopic, histological, manometric, and esophageal 24-h ambulatory pH criteria </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Mean <z:chebi fb="0" ids="15647">LTB4</z:chebi> levels were significantly higher in both endoscopically and histologically identified erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo> and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> patients, compared with <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, <z:chebi fb="0" ids="15551">PGE2</z:chebi> levels did not differ significantly among endoscopic or histological groups </plain></SENT>
<SENT sid="6" pm="."><plain>When eicosanoid levels and composite symptom score (frequency score x severity score summed over five symptoms) were analyzed, no significant associations were found between <z:chebi fb="0" ids="15647">LTB4</z:chebi> or <z:chebi fb="0" ids="15551">PGE2</z:chebi> levels and the composite symptom score </plain></SENT>
<SENT sid="7" pm="."><plain>There was no correlation between tissue eicosanoid levels and either the degree of esophageal acid exposure by ambulatory pH monitoring or the lower esophageal sphincter resting pressure as assessed by esophageal motility </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment with <z:chebi fb="14" ids="7772">omeprazole</z:chebi> 20 mg by mouth daily for 6 wk significantly reduced both <z:chebi fb="0" ids="15647">LTB4</z:chebi> and <z:chebi fb="0" ids="15551">PGE2</z:chebi> levels (p &lt; 0.05) and was associated with significant improvement of symptoms and the endoscopic and histological appearance of the esophagus in 25 patients </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These results suggest that <z:chebi fb="0" ids="15647">LTB4</z:chebi>, a prominent product of <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> metabolism in neutrophils, mediates the inflammatory phenomena of reflux <z:hpo ids='HP_0100633'>esophagitis</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>The role of <z:chebi fb="0" ids="15647">LTB4</z:chebi> and <z:chebi fb="0" ids="15551">PGE2</z:chebi> in the induction of symptoms in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> remains unclear </plain></SENT>
</text></document>